Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, March 19, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Jason McCarthy Maintained (ATNM) at Strong Buy with Increased Target to $30 on, Mar 19th, 2024
Jason McCarthy of Maxim Group, Maintained "Actinium Pharmaceuticals, Inc." (ATNM) at Strong Buy with Increased Target from $20 to $30 on, Mar 19th, 2024.
Jason has made no other calls on ATNM in the last 4 months.
There is 1 other peer that has a rating on ATNM. Out of the 1 peers that are also analyzing ATNM, 0 agree with Jason's Rating of Hold.
This is the rating of the analyst that currently disagrees with Jason
- Yuan Zhi of "B. Riley Securities" Maintained at Strong Buy with Decreased Target to $16 on, Monday, December 11th, 2023
